πŸ”¬Deep Research

BHVN β€” Biohaven Ltd Β· catalysts, narrative & risks

Β·24 sourcesBHVN forecast β†’

Snapshot

Biohaven Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company in the biotechnology sector, trading around US$12 (52-week range US$7.48–18.57) with an intraday market capitalization of approximately US$1.83 billion and a beta of 3.20 [22]. The company is pre-revenue with a large accumulated loss (net income of roughly βˆ’US$587 million trailing twelve months; EPS of βˆ’US$4.56) and carries a heavy balance-sheet leverage (debt/equity near 2,430%) [22]. Below is a critical synthesis of recent developments, the bull/bear debate, risks, and the calendar, drawing primarily on material from the last ~1–3 months.

Recent catalysts (approximately July–October 2026)


AI-assisted research from the K3vl4r desk β€” not personalized investment advice. More research β†’